HCM
TLSI icon

Highbridge Capital Management’s TriSalus Life Sciences TLSI Stock Holding History

Highbridge Capital Management’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-214,545
Closed -$1.18M – 348
2024
Q2 		$1.18M Buy
+214,545
New +$1.82M 0.04% 100

Other funds holding TLSI

WAP
Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
EAM
Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return
CWM
Connecticut Wealth Management Farmington, Connecticut $2.39B AUM 17.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Highbridge Capital Management's TLSI Position: Q3 2024 in Review

Highbridge Capital Management sold out of TriSalus Life Sciences (TLSI) in Q3 2024, closing a stake of 214,545 shares — an estimated $1.18M sold.

Highbridge Capital Management first reported a position in TLSI in Q2 2024 and held it in 1 quarter. The position peaked at $1.18M in Q2 2024. 32 funds tracked by Wall St. Rank hold TLSI as of Q3 2024.

  • Highbridge Capital Management reported no remaining TriSalus Life Sciences position as of Q3 2024 after selling out during the quarter.
  • Highbridge Capital Management sold 214,545 TriSalus Life Sciences shares in Q3 2024, an estimated $1.18M.
  • Highbridge Capital Management first reported a position in TriSalus Life Sciences in Q2 2024 and held it in 1 quarter.
  • Highbridge Capital Management's TriSalus Life Sciences position peaked at $1.18M in Q2 2024.
  • 32 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2024.

Based on Highbridge Capital Management's 13F filing for Q3 2024, filed 8 Nov 2024.